Systemic sclerosis & Raynaud's
Clinical and immunological features of patients with cancer-associated systemic sclerosis: An observational study
Authors' conclusion
In addition to anti-RNA Pol 3 antibodies, anti-SSA antibodies associated with an increased risk of cancer in SSc patients. Interstitial lung disease was a risk factor specifically for lung cancer and cancers diagnosed more than 3 years after SSc diagnosis.
Study context
- Population
- Patients with systemic sclerosis (SSc), single centre74 (16%) with cancer
- Participants
- 464 patients
- Exposure
- SSc patients with vs without associated malignancy
- Cancern = 74
- Outcome
- Clinical and immunological predictive factors of cancer-associated SSc
Methodological detailsmonocentric, observational, multivariate analysis
- Monocentric
- Observational
- Multivariate analysis
Main finding
As reported in the abstract
Independent risk factors of overall cancer (multivariate analysis)
Odds ratio (95% CI)P value
Anti-RNA Pol 3 antibodies
4.12(1.6–10.7)
P < 0.01Anti-SSA antibodies
2.43(1.1–5.4)
P < 0.05Observational data: associations, not effects.
Further findings
- Cancer prevalence and type
- 16% · 74
- Cancer prevalence and type — Cancer diagnosed <3 years before or after SSc diagnosis
- 23 patients (31%)
Lung cancer and cancer >3 years after SSc diagnosis (subgroups)
- ILD and anti-topoisomerase antibodies associated with increased risk
Original publication
Clinical and immunological features of patients with cancer-associated systemic sclerosis: An observational study. Joint Bone Spine. Published 25 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →